Trial · NCT07914101
Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer
NCT07914101, Phase 3, Not yet recruiting, Assiut University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer. Trials, record NCT07914101. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07914101
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer
- NCT number
- NCT07914101
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 71 participants, estimated
- Lead sponsor
- Assiut University
- Conditions
- Bladder Cancer, TURBT, Radiotherapy
- Interventions
- Transurethral Resection of Bladder Tumor, Sequential Systemic Chemotherapy, radiotherapy
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of objective Response rate (ORR) and Disease control rate (DCR) | 4-6 weeks after completion of RT | Evaluate the Clinical efficacy including Objective Response rate (ORR) and Disease control rate (DCR) at 4-6 weeks after finishing RT. |
| Primary | Assessment of Toxicity of Treatment | Baseline | Evaluate Toxicity of Treatment using Common Terminology Criteria for Adverse Events (CTCAE V.5) |
| Primary | Assessment of Toxicity of Treatment | Baseline | Assessment of treatment-related toxicity according to health-related quality of life using the EQ-5D questionnaire |
| Secondary | Assess the Time to local disease progression | From treatment initiation until the end of the follow up ( 12 months follow up ) | Time from the date of treatment initiation to the date of documented local disease progression |
| Secondary | Assess the Time to EFS | From treatment initiation until progression or death | Time from the date of treatment initiation to Event free survival |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07914101
GET https://conductscience.org/api/trials/v1/NCT07914101/registered